Profile data is unavailable for this security.
About the company
Nuformix plc is a United Kingdom-based pharmaceutical development company, which is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurpose. The Company aims to use its expertise in discovering, developing, and patenting novel drug forms, with improved physical properties, to develop new products that are differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Its pipeline includes NXP001, NXP002 and NXP004. NXP001 is a form of the drug aprepitant that is marketed as a product in the oncology supportive care setting. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for idiopathic pulmonary fibrosis. NXP004 is a form of Olaparib, which is used for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation and has since secured similar approvals in breast, pancreatic and prostate cancers.
- Revenue in GBP (TTM)0.00
- Net income in GBP-652.59k
- Incorporated2015
- Employees3.00
- LocationNuformix PLC6th Floor, 60 Gracechurch StreetLONDON EC3V 0HRUnited KingdomGBR
- Phone+44 122 362 7222
- Websitehttps://nuformix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kanabo Group PLC | 1.14m | -8.18m | 1.42m | 17.00 | -- | 0.2402 | -- | 1.25 | -0.013 | -0.013 | 0.0018 | 0.0094 | 0.1054 | 16.28 | 43.85 | 67,058.82 | -75.70 | -75.83 | -81.16 | -83.33 | 7.89 | -- | -718.33 | -1,267.35 | 2.72 | -63.43 | 0.0337 | -- | 48.42 | -- | -16.26 | -- | -- | -- |
| BSF Enterprise PLC | 52.84k | -1.11m | 2.57m | 10.00 | -- | 0.9447 | -- | 48.59 | -0.0093 | -0.0093 | 0.0004 | 0.0212 | 0.0163 | 0.9496 | 4.07 | 5,284.00 | -34.25 | -35.35 | -37.51 | -38.06 | -34.37 | -- | -2,107.34 | -4,267.99 | 1.38 | -710.58 | 0.00 | -- | -8.61 | -- | 33.41 | -- | -- | -- |
| Nuformix PLC | 0.00 | -652.59k | 4.64m | 3.00 | -- | 5.92 | -- | -- | -0.0004 | -0.0004 | 0.00 | 0.0004 | 0.00 | -- | -- | -- | -65.61 | -- | -88.76 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 82.08 | -- | -- | -- |
| CRISM' Therapeutics Corp | 25.00k | -1.49m | 7.24m | 0.00 | -- | 4.20 | -- | 289.72 | -0.0458 | -0.0469 | 0.0008 | 0.0333 | 0.012 | -- | 0.0305 | -- | -71.61 | -9.33 | -88.05 | -9.68 | 72.00 | -- | -5,952.00 | -32,053.62 | -- | -- | 0.00 | -- | -- | -- | 69.17 | -- | -41.03 | -- |
| Oxford Biodynamics PLC | 1.10m | -11.15m | 12.23m | 44.00 | -- | 5.00 | -- | 11.17 | -0.0096 | -0.0096 | 0.0008 | 0.0006 | 0.1085 | 2.22 | 1.21 | -- | -110.46 | -70.62 | -148.46 | -89.03 | 47.67 | -- | -1,018.54 | -1,715.57 | 0.8005 | -30.88 | 0.8208 | -- | 72.17 | 19.15 | 3.58 | -- | -11.79 | -- |
| Probiotix Health PLC | 2.22m | -736.00k | 12.26m | 4.00 | -- | 6.85 | -- | 5.52 | -0.005 | -0.005 | 0.0146 | 0.0113 | 1.05 | 18.57 | 3.01 | 555,250.00 | -34.67 | -21.03 | -46.17 | -27.30 | 53.17 | 54.10 | -33.14 | -26.58 | 3.99 | -- | 0.00 | -- | 12.55 | 36.47 | -13.39 | -- | -41.50 | -- |
| CRUSHMETRIC Group Ltd | -100.00bn | -100.00bn | 20.62m | 17.00 | -- | 1.25 | -- | -- | -- | -- | -- | 0.0678 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.027 | -- | 0.0898 | -- | -- | -- | -- | -- | -- | -- |
